These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 33867479)
1. New treatments in advanced gastrointestinal stromal tumor. Serrano C Curr Opin Oncol; 2021 Jul; 33(4):323-328. PubMed ID: 33867479 [TBL] [Abstract][Full Text] [Related]
2. New Tyrosine Kinase Inhibitors for the Treatment of Gastrointestinal Stromal Tumors. Serrano C; Bauer S Curr Oncol Rep; 2022 Feb; 24(2):151-159. PubMed ID: 35061196 [TBL] [Abstract][Full Text] [Related]
3. Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial. Jones RL; Serrano C; von Mehren M; George S; Heinrich MC; Kang YK; Schöffski P; Cassier PA; Mir O; Chawla SP; Eskens FALM; Rutkowski P; Tap WD; Zhou T; Roche M; Bauer S Eur J Cancer; 2021 Mar; 145():132-142. PubMed ID: 33465704 [TBL] [Abstract][Full Text] [Related]
4. Avapritinib in the treatment of PDGFRA exon 18 mutated gastrointestinal stromal tumors. Smrke A; Gennatas S; Huang P; Jones RL Future Oncol; 2020 Aug; 16(22):1639-1646. PubMed ID: 32517495 [TBL] [Abstract][Full Text] [Related]
5. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. Heinrich MC; Jones RL; von Mehren M; Schöffski P; Serrano C; Kang YK; Cassier PA; Mir O; Eskens F; Tap WD; Rutkowski P; Chawla SP; Trent J; Tugnait M; Evans EK; Lauz T; Zhou T; Roche M; Wolf BB; Bauer S; George S Lancet Oncol; 2020 Jul; 21(7):935-946. PubMed ID: 32615108 [TBL] [Abstract][Full Text] [Related]
6. Gastrointestinal Stromal Tumor: Challenges and Opportunities for a New Decade. Serrano C; George S Clin Cancer Res; 2020 Oct; 26(19):5078-5085. PubMed ID: 32601076 [TBL] [Abstract][Full Text] [Related]
7. Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib. Janku F; Abdul Razak AR; Chi P; Heinrich MC; von Mehren M; Jones RL; Ganjoo K; Trent J; Gelderblom H; Somaiah N; Hu S; Rosen O; Su Y; Ruiz-Soto R; Gordon M; George S J Clin Oncol; 2020 Oct; 38(28):3294-3303. PubMed ID: 32804590 [TBL] [Abstract][Full Text] [Related]
8. Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. Kang YK; George S; Jones RL; Rutkowski P; Shen L; Mir O; Patel S; Zhou Y; von Mehren M; Hohenberger P; Villalobos V; Brahmi M; Tap WD; Trent J; Pantaleo MA; Schöffski P; He K; Hew P; Newberry K; Roche M; Heinrich MC; Bauer S J Clin Oncol; 2021 Oct; 39(28):3128-3139. PubMed ID: 34343033 [TBL] [Abstract][Full Text] [Related]
9. [Gastrointestinal stromal tumors (GIST)]. Jaros D; Bozic B; Sebesta C Wien Med Wochenschr; 2023 Jun; 173(9-10):201-205. PubMed ID: 36155864 [TBL] [Abstract][Full Text] [Related]
10. [Clinicopathological features and prognosis of gastrointestinal stromal tumors with Shen YY; Li XQ; Yang LX; Fang Y; Nie MM; He ZR; Hou YY; Cao H; Wang M; Shen KT Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):804-813. PubMed ID: 34530562 [No Abstract] [Full Text] [Related]
11. [Advanced GIST: Which treatments in 2022?]. Mas L; Bachet JB Bull Cancer; 2022 Oct; 109(10):1082-1087. PubMed ID: 35934543 [TBL] [Abstract][Full Text] [Related]
12. New therapeutic agents in gastrointestinal stromal tumours. Falkenhorst J; Hamacher R; Bauer S Curr Opin Oncol; 2019 Jul; 31(4):322-328. PubMed ID: 31033566 [TBL] [Abstract][Full Text] [Related]
13. Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy. George S; Jones RL; Bauer S; Kang YK; Schöffski P; Eskens F; Mir O; Cassier PA; Serrano C; Tap WD; Trent J; Rutkowski P; Patel S; Chawla SP; Meiri E; Gordon M; Zhou T; Roche M; Heinrich MC; von Mehren M Oncologist; 2021 Apr; 26(4):e639-e649. PubMed ID: 33453089 [TBL] [Abstract][Full Text] [Related]
14. [New drug approvals: Ripretinib for advanced gastrointestinal stromal tumors (GIST) in fourth or later-line therapy]. Lemaître J; Watson S Bull Cancer; 2022 Mar; 109(3):250-252. PubMed ID: 35094842 [No Abstract] [Full Text] [Related]
15. Avapritinib in unresectable or metastatic gastrointestinal stromal tumor with PDGFRA exon 18 mutation: safety and efficacy. Henriques-Abreu M; Serrano C Expert Rev Anticancer Ther; 2021 Oct; 21(10):1081-1088. PubMed ID: 34404327 [TBL] [Abstract][Full Text] [Related]
16. Financial Implications of Avapritinib for Treatment of Unresectable Gastrointestinal Stromal Tumors in Patients With a PDGFRA Exon 18 Variant or After 3 Previous Therapies in a Hypothetical US Health Plan. Proudman D; Miller A; Nellesen D; Gomes A; Mankoski R; Norregaard C; Sullivan E JAMA Netw Open; 2020 Nov; 3(11):e2025866. PubMed ID: 33201235 [TBL] [Abstract][Full Text] [Related]
17. Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFRα inhibitor for treatment of gastrointestinal stromal tumors. Banks E; Grondine M; Bhavsar D; Barry E; Kettle JG; Reddy VP; Brown C; Wang H; Mettetal JT; Collins T; Adeyemi O; Overman R; Lawson D; Harmer AR; Reimer C; Drew L; Packer MJ; Cosulich S; Jones RD; Shao W; Wilson D; Guichard S; Fawell S; Anjum R Sci Transl Med; 2020 Apr; 12(541):. PubMed ID: 32350132 [TBL] [Abstract][Full Text] [Related]
18. The role of KIT in the management of patients with gastrointestinal stromal tumors. Hornick JL; Fletcher CD Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861 [TBL] [Abstract][Full Text] [Related]
19. Avapritinib for metastatic or unresectable gastrointestinal stromal tumors. Alzofon N; Jimeno A Drugs Today (Barc); 2020 Sep; 56(9):561-571. PubMed ID: 33025950 [TBL] [Abstract][Full Text] [Related]